Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elraglusib, Retifanlimab, and mFOLFIRINOX in Advanced Pancreatic Adenocarcinoma
NCT06896188Phase 1Recruiting
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of elraglusib and retifanlimab in pancreatic adenocarcinoma (PDAC). Primary endpoint: Dose Limiting Toxicities at 28 days. Started Sep 2025; status: recruiting.
02
Drugs
elraglusibretifanlimab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06896188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06896188.